more_reports

Study Shows 93% Cough Suppression With Co.'s Drug

  ()
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market."

Could This Stock Be the Next Bellus Cough Treatment?

Contributed Opinion
  ()
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy.

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride

Research Report
  ()
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report.

Healthcare AI Company Achieves Key Milestones and Secures New Partnerships

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects.

Biopharma Co. Reports Strong FQ224 Results Driven

Research Report
  ()
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX).

Texas Biotech Announces Plans for Preclinical Obesity Studies

Research Report
  ()
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note.

AI Health Stock Heading Higher Expert Says

Contributed Opinion
  ()
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher.

California Biotech Reports Positive Phase 3 Results

Research Report
  ()
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.

Chicago Alt. Medicine Co. Announces US$50M Share Repurchase Program

Research Report
  ()
In a Roth MKM research note, analyst Nick Anderson noted that Verano Holdings Corp. (VRNO:CSE; VRNOF:OTCQX) was well-positioned to generate increasing cash flow.
Tags: Cannabis

Clean Tech Subsidiary Finds Manufacturer for Wound Solution

  ()
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic.

Is This Pharma Co. the Next Eli Lilly?

  ()
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly.

Positive Phase 2 Clinical Trial Results Announced for Drug Treating Idiopathic Hypersomnia

  ()
Zevra Therapeutics Inc. (ZVRA:NASDAQ), a company specializing in rare disease therapeutics, has announced positive final results from its Phase 2 clinical trial evaluating the safety and tolerability of KP1077 for treating idiopathic hypersomnia.

Rare Disease Co. Presents Positive Phase 2 KP1077 Data

Research Report
  ()
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note.

Co. Targets More Verticals in Safe Supply

  ()
This Canadian firm, with a streaming business model, intends to invest in two additional segments of the safe supply ecosystem. Here, learn more about this approach to reducing harms from illegal drugs.

Co. Expands Telehealth Contract to New State

  ()
Reliq Health Technologies Inc. announced that a large U.S. health group has expanded its contract with the telehealth company to cover facilities in a new state. Read why one analyst thinks the stock is a Buy.

New Healthcare AI Partnership Aims to Transform Health Risk Assessments

  ()
Treatment.com AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector.

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Pharma Co. Secures $650M Strategic Financing

Research Report
  ()
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine.

Pharma Stock Focuses on Successful Ensifentrine Launch

Research Report
  ()
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note.

New COPD Drug Slated for Approval Decision This June

  ()
Ahead of the upcoming PDUFA date, several analysts recommend the biopharma behind this treatment as a Buy. Read on to learn why.

Pharma Stock Nears FDA Approval

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval.

Investor Conference Highlights New Strategic Directions for Addressing Opioid Crisis

  ()
Safe Supply Streaming has provided an update on Safety Strips, its recent acquisition. Read on for more about how this impacts the company's battle against the opioid crisis.